GlassScriptPhysician profile
Rachael Riggins
NPI 1780152330
$18,688.40
in general payments reported to CMS, 2019-2025
54 companies · $4,197 in 2025
The $4,197 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,368 · 2022: $2,234 · 2023: $2,501 · 2024: $8,388 · 2025: $4,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,100 · Travel and Lodging: $1,890 · Education: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,694.46 |
| Consulting Fee | $2,100.00 |
| Travel and Lodging | $1,890.11 |
| Education | $402.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $4,900.68 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Abbvie INC. | $2,657.67 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $1,154.15 | 2022-2025 | Ultomiris, Soliris |
| Ucb, INC. | $983.34 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $968.37 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $849.88 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $769.66 | 2021-2025 | |
| Sk Life Science, INC. | $695.75 | 2021-2025 | |
| Biogen, INC. | $640.02 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Emd Serono, INC. | $520.55 | 2022-2025 | Mavenclad |
| Neurelis, INC. | $379.48 | 2021-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $358.02 | 2021-2025 | Nuplazid, Daybue |
| Lilly USA, LLC | $327.21 | 2021-2025 | Emgality, Kisunla, Amyvid |
| Lundbeck LLC | $296.94 | 2021-2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $295.79 | 2024-2025 | Ponvory |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Riggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.